|
|
|
IBCSG 24-02 / BIG 2-02 (SOFT)
A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer Suppression of Ovarian Function Trial (SOFT)
DESIGN
Co-SOFT Substudy
The Cognitive Function Substudy is investigating cognitive function for patients participating in the SOFT trial in selected centers. |
SOFT-EST Substudy
The SOFT-EST Substudy investigates estrogen levels at different timepoints during the first 4 years of protocol treatment among patients receiving triptorelin plus either tamoxifen (arm B) or exemestane (arm C). |
|
Study ChairsBIG: Dr. Prue Francis - Melbourne, Australia
US Intergroup: Dr. Gini Fleming - Chicago, USA
StatisticianDr. Meredith Regan
Trial CoordinatorsKarolyn Scott, Jocelyn Swick, Kris Rickard, Tara Scolese
IBCSG Data Management Center/FSTRF 4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg24-26_STP@fstrf.org
Date of ActivationAugust 4, 2003
Targeted Accrual3000 patients
 Co-SOFT Substudy Results & Publications Pathology
News
01.02.2010:
The impact of peritumoral vascular invasion on outcome in IBCSG Trials VIII and IX
27.01.2010:
First issue of SOLE flash, the short newsletter for IBCSG 35-07 SOLE
11.01.2010:
The latest information about the IBCSG Annual Meeting 2010 is available online.
All News
|
|